Prinomastat

Prinomastat (also known as AG3340) is a synthetic small molecule inhibitor that targets matrix metalloproteinases (MMPs). It was developed by Agouron Pharmaceuticals, a subsidiary of Pfizer, for the treatment of various cancers. However, clinical trials were discontinued due to lack of efficacy.

Mechanism of Action

Prinomastat inhibits MMPs, a group of enzymes that degrade the extracellular matrix, a key component of tissues and organs. By inhibiting these enzymes, Prinomastat can potentially prevent the spread of cancer cells and the formation of new blood vessels (angiogenesis), which tumors need to grow.

Clinical Trials

Prinomastat was tested in several clinical trials for its potential use in treating various types of cancer, including lung cancer, prostate cancer, and breast cancer. However, the trials were discontinued due to lack of efficacy.

Side Effects

The most common side effects reported in clinical trials were nausea, vomiting, and fatigue. Some patients also experienced musculoskeletal pain.

See Also

• Matrix metalloproteinase
• Cancer
• Clinical trial

References

Prinomastat Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski